328 related articles for article (PubMed ID: 20088842)
21. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
22. [Iron overload in sickle cell anemia : a study of 94 patients].
Hafsia R; Belakhal F; Ben Salah N; Gouider E; Elborgi W
Tunis Med; 2011 Jun; 89(6):548-52. PubMed ID: 21681718
[TBL] [Abstract][Full Text] [Related]
23. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
24. Consequences and management of iron overload in sickle cell disease.
Porter J; Garbowski M
Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
[TBL] [Abstract][Full Text] [Related]
25. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
[TBL] [Abstract][Full Text] [Related]
27. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
28. The dangers of iron overload: bring in the iron police.
Lambing A; Kachalsky E; Mueller ML
J Am Acad Nurse Pract; 2012 Apr; 24(4):175-83. PubMed ID: 22486832
[TBL] [Abstract][Full Text] [Related]
29. Iron overload: consequences, assessment, and monitoring.
Taher AT; Musallam KM; Inati A
Hemoglobin; 2009; 33 Suppl 1():S46-57. PubMed ID: 20001632
[TBL] [Abstract][Full Text] [Related]
30. Clinical and economic burden of infused iron chelation therapy in the United States.
Payne KA; Desrosiers MP; Caro JJ; Baladi JF; Lordan N; Proskorovsky I; Ishak K; Rofail D
Transfusion; 2007 Oct; 47(10):1820-9. PubMed ID: 17880607
[TBL] [Abstract][Full Text] [Related]
31. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
32. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
33. Impact of iron overload in myelodysplastic syndromes.
Fenaux P; Rose C
Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
[TBL] [Abstract][Full Text] [Related]
34. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
35. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
Musallam KM; Cappellini MD; Wood JC; Taher AT
Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
[TBL] [Abstract][Full Text] [Related]
36. Iron-chelating therapy for transfusional iron overload.
Musallam KM; Taher AT
N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
[No Abstract] [Full Text] [Related]
37. Iron-chelating therapy for transfusional iron overload.
Solomon LR
N Engl J Med; 2011 Apr; 364(15):1475-6; author reply 1477. PubMed ID: 21488788
[No Abstract] [Full Text] [Related]
38. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
39. Concepts and goals in the management of transfusional iron overload.
Porter JB
Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
[TBL] [Abstract][Full Text] [Related]
40. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
Porter JB; Davis BA
Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
